Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Re-engineered AAV-LPL
Therapeutic Area : Genetic Disease
Study Phase : Undisclosed
Sponsor : Innovation, Science and Economic Development Canada
Deal Size : $0.4 million
Deal Type : Collaboration
Virica Biotech Announces Collaboration with the Government of Canada
Details : Funding supports Virica’s collaboration with the National Research Council of Canada’s Cell and Gene Therapy Challenge program to enhance the manufacturing of an affordable, AAV-LPL, a gene therapy being developed for people with debilitating lipopro...
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 02, 2022
Lead Product(s) : Re-engineered AAV-LPL
Therapeutic Area : Genetic Disease
Highest Development Status : Undisclosed
Sponsor : Innovation, Science and Economic Development Canada
Deal Size : $0.4 million
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?
Reset All
